Analysed IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) News Sources
What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders
06-06-2026
yahoo.com
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
08-06-2026
yahoo.com
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
09-06-2026
yahoo.com
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Inflation Data
09-06-2026
yahoo.com
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
10-06-2026
yahoo.com
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study
11-06-2026
yahoo.com
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
15-06-2026
yahoo.com
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
17-06-2026
yahoo.com
What is the current price of IDEAYA BIOSCIENCES INC (IDYA:NASDAQ)?
The current price of IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) is $36.15.
IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) absolute price change since previous trading day?
The absolute price change of IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) since the previous trading day is $-0.84.
IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) percentage price change since previous trading day?
The percentage price change of IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) since the previous trading day is -2.2709%.
What is the most recent average sentiment score for IDEAYA BIOSCIENCES INC (IDYA:NASDAQ)?
The most recent average sentiment score for IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for IDEAYA BIOSCIENCES INC (IDYA:NASDAQ)?
The most recent sentiment for IDEAYA BIOSCIENCES INC (IDYA:NASDAQ) is .
SEC-8K** Filing Available For IDEAYA BIOSCIENCES INC (IDYA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.